This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Yup only 1p down now.

cheers GF.

Excelent news just out and one reason for the recovery. Snobby broker firm just given out the following................


"...Insinger de Beaufort London have issued a research note today with a short term price target of 200p. This is on the basis of the Genvax news and the current negotiating with potential licensee companies for the ruthenium technology".

Buy buy buy.

cheers GF.

Now back at evens for the day.

cheers GF.

There is speculation that the DNA platform technology company Genvax could be a World beater and be a bigger earner than the Ruthenium technology but I am not convinced until the March evaluation results..watch this space.

I have no complaints about today with mmg..... I have suffered elsewhere but thankfully not here... stay in. Rob

We had a great bullish reversal today with the sp down initially and then making a come-back in the afternoon..if this pattern continues tomorrow we could see more buyers returning and the sp climbing higher once again.
Hopefully good news from Ruthenium and Genvax within the next 4 weeks will push this to 200p as per the latest brokers note which gf mentioned today.Next a licencing deal with a big pharma will give MMG the financial consideration it deserves and the sp will push even higher than before.

I agree totaly.

cheers GF.

gf.
If the Ruthenium drug gets to market in 3 years time we could have a real winner on our hands, and a share price to match...1500p easily in 2009...and Genvax could add another 500p..

Yes and I still think your target of 400p could be on the cards for the end of this year.

cheers GF.

23 February 2005
Latest News In Life Sciences



MMI further expands collaboration
By Business Weekly, 22 February 2005, viewed 37 times, emailed 26 times


Medical Marketing International Group plc, the Cambridge pharmaceutical development company has further expanded the collaboration between the University of Edinburgh and its wholly owned subsidiary Oncosense.


Medical Marketing International Group plc, the Cambridge pharmaceutical development company has further expanded the collaboration between the University of Edinburgh and its wholly owned subsidiary Oncosense.

The team developing Ruthenium anticancer complexes will now include Dr James Hoeschele a co-inventor of the best selling platinum based chemotherapy drug Carboplatin.

Dr Hoeschele, an acknowledged expert in the field of anti-tumour precious metal complexes, has more than 30 years experience working in both industry and academia.

He is named as inventor on 12 patents relating to platinum based complexes used as chemotherapy agents and has published 50 reviewed scientific papers on platinum based chemotherapy drugs including studies of pharmacokinetics, biodistribution and their structure activity relationships.

Prof Peter Sadler and Dr Duncan Jodrell, the inventors of the Ruthenium based anti-cancer drugs, have shown that certain ruthenium complexes appear to have significant advantages over platinum-based drugs that are widely used in the clinic.

Oncosense is funding Prof Sadlers department to achieve commercial targets in the development of Ruthenium compounds.

cheers GF.

Added this morning at 116.4p and a few at 115p. I hope to see a glorious March with this stock.

cheers GF.

Lets not forget recent Broker upgrades upgraded after the analysts meeting with the company..............................

Brewin Dolphin have a 160p short term target ..and Nomura believe it or not a collosal 400p plus ..giving a valuation of 250m...!

Insinger de Beaufort London have issued a research note today with a short term price target of 200p. This is on the basis of the Genvax news and the current negotiating with potential licensee companies for the ruthenium technology".

cheers GF.

A mention in the Killick Morning Note today..


http://www.killikmorningnote.co.uk/

And a mention here aswell 200p short term target............

Trading View
Independent Banking
Source: Insinger de Beaufort, Bloomberg

Accelerating development pipeline

Significant commercial potential: MMI is an emerging biotechnology company
focused in cancer and infectious diseases, both areas of significant commercial
potential. MMIs strategy is to develop drugs to Phase II clinical trial stage and then
commercialise via out-licencing agreements with pharmaceutical companies. Thin
pipelines and patent expiries have acted as a catalyst for a large number of deals
with small cap biotechs such as MMI, even for products which are relatively early
stage. For example a deal with Oxxon Therapeutics could potentially be worth up to
44m in up-front and milestone payments in order to access Xenovas early stage
cancer DISC HSV vector technology. It is also interesting to note recent benchmark
deals for pre clinical early stage compounds with promise - Novartis paid c.$157m to
Xenon and J&J is paying up to $295m in a deal excluding royalties to Arena.
MMI has four R&D divisions:
a) Oncosense (wholly owned) - technology based around the precious metal
ruthenium which is potentially up to 15 times more efficacious than the
most potent platinum anticancer drug.
b) Genvax (JV) - developing DNA vaccines for cancer with Southampton
University/Cancer Research UK Leukaemia Research Fund
c) Viratis (JV) - viral infections with Kings College London
d) Endozyme (wholly owned) - drug resistant Infections working with
Cambridge University/Novartis
MMI also provides technical services to UK academic and commercial institutions
which apart from generating revenues, also provides a stream of potential in -
licensing opportunities.
Tight cost control: Given a current cash balance of 2.6m, MMI has enough cash to
last until Q1 06. Whilst it would not be prudent to discount a future fund raising,
additional cash inflows may come from licensing deals. Furthermore MMIs R&D
expenses are contained via collaborat ions outlined above and also contracting out
to CROs (clinical research organisations).
Strong management: MMIs management has been strengthened recently with the
appointment of Dr James Hoeschele (co-discoverer of Carboplatin, a platinum based
anti-cancer treatment) to work on MMI's leading ruthenium compounds which are
expected to reach the market during 2008.
Strong newslow: During the course of 2005 MMI aims to bring 6 new products into
Phase I/II clinical trials including compounds from MMIs ruthenium based
anticancer programme. The JV Genvax is due to report on Phase II trials treating
follicular lymphoma on the 18th March. These results are expected to be positive
and as such could drive the share price higher despite the recent good run. MMI is
also currently negotiating with a number of potential licensee companies for the
ruthenium technology. Conservative target price of 200p (DCF) generates 50% plus
upside to current share price which 1s 111.5p.
Medical Marketing International (MMG.L) Trading Buy
Biotechnology
UK Equity Research
Alexien Eve Isaac +44 (0)20 7190 7197
Paul Bethell, CFA +44 (0)20 7190 7198
researchldn@insinger.com
Previous close price (p):
116.0
Market cap (m):
62.0
Target Price (p):
200.0
Year End:
March
Net cash position:
2.6m




cheers GF.http://www.bendavidson.co.uk/MMI-02-23-05-trading-view.pdf

I'm out of NLR from yesterday gf although I still hold a small parcel of them.I intend to buy more MMG shares with the proceeds as I think they have further to go..cheers.

More or less thinking the same as you Mitzy although I have transfered money from NLR to MMG I have kept two tranches of NLR.

cheers GF.

GF

Are you keeping you eye on GMC. Sorry about the hijack.

MS

Hi Mickey, no got out last week. Building up a big position in this one. Think it will go for Mitzys 400p target and some.

cheers GF.

Well I rekon 200p by the end of the year gf but say 350p within the next 18 months as the products enter and finish phase 2 trials..no point in selling these just yet..!

Would appear that the SP is going to drift down on small sells and thin volume. MM s will use this opportunity to obtain some stock at lower levels ready for a run up to the 18th.. Not seeing the buyers coming in like we where,a few weeks ago so the MM s can slowly lower the price.110p should hold but wouldnt be to suprised to see 100p. However if SP is going to these levels then i would imagine it will be before the 10th as we run up to the 18th